









Markets
/
Stocks
/
nasdaq-aldx
/

Aldeyra Therapeutics Inc

ALDX

4.690USD

-0.120-2.49%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

282.16MMarket Cap

LossP/E TTM



Aldeyra Therapeutics Inc

4.690

-0.120-2.49%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Aldeyra Therapeutics Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aldeyra Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

125 / 407

Overall Ranking

253 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

9.667

Target Price

+100.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Aldeyra Therapeutics Inc Highlights

StrengthsRisks

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

Fairly Valued

The company’s latest PE is -6.50, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 34.71M shares, decreasing 9.14% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 39.47K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.24.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 7.15, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.15

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.96

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Aldeyra Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 6.20, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -6.50, which is -77.44% below the recent high of -1.47 and -75.99% above the recent low of -11.44.

Score

Industry at a Glance

Previous score

6.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 125/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Aldeyra Therapeutics Inc is 9.50, with a high of 13.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

9.667

Target Price

+100.97%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Aldeyra Therapeutics Inc

ALDX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.35, which is lower than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 5.48 and the support level at 4.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.23

Change

0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.108

Sell

RSI(14)

35.064

Neutral

STOCH(KDJ)(9,3,3)

23.497

Sell

ATR(14)

0.275

Low Volatility

CCI(14)

-183.157

Sell

Williams %R

83.902

Oversold

TRIX(12,20)

-0.321

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

4.916

Sell

MA10

5.011

Sell

MA20

5.178

Sell

MA50

5.291

Sell

MA100

5.091

Sell

MA200

4.631

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 57.96%, representing a quarter-over-quarter decrease of 3.41%. The largest institutional shareholder is The Vanguard, holding a total of 3.50M shares, representing 5.85% of shares outstanding, with 7.33% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Knoll Capital Management, LLC

5.48M

Perceptive Advisors LLC

4.05M

-16.90%

The Vanguard Group, Inc.

Star Investors

3.50M

-5.82%

BlackRock Institutional Trust Company, N.A.

3.54M

+3.73%

Ardsley Advisory Partners LP

2.05M

+17.14%

AQR Capital Management, LLC

1.47M

+275.44%

Brady (Todd C)

1.42M

+23.16%

Kingdon Capital Management, L.L.C.

1.33M

+70.96%

Geode Capital Management, L.L.C.

1.15M

+0.77%

683 Capital Management LLC

1.08M

+126.89%

Risk Assessment

Currency: USD Updated: 2025-11-07

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.47. The company's beta value is 0.84. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.